Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Senolytics have the potential to extend healthspan by selectively killing senescent cells (SCs), but senolytics that target Bcl-xl may cause platelet toxicity. Here, the authors generated a Bcl-xl proteolysis-targeting chimera (PROTAC) senolytic, which effectively clears SCs and rejuvenates tissue s...
Main Authors: | Yonghan He, Xuan Zhang, Jianhui Chang, Ha-Neui Kim, Peiyi Zhang, Yingying Wang, Sajid Khan, Xingui Liu, Xin Zhang, Dongwen Lv, Lin Song, Wen Li, Dinesh Thummuri, Yaxia Yuan, Janet S. Wiegand, Yuma T. Ortiz, Vivekananda Budamagunta, Jennifer H. Elisseeff, Judith Campisi, Maria Almeida, Guangrong Zheng, Daohong Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-04-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-15838-0 |
Similar Items
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
by: Yonghan He, et al.
Published: (2020-07-01) -
The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
by: Anuj K. Sharma, et al.
Published: (2020-05-01) -
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
by: Ryan Kolb, et al.
Published: (2021-02-01) -
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
by: Yonghan He, et al.
Published: (2020-07-01) -
Proteolysis targeting chimeras (PROTACs) in cancer therapy
by: Alberto Ocaña, et al.
Published: (2020-09-01)